Mayne Pharma Group Ltd - Asset Resilience Ratio

Latest as of June 2025: 4.00%

Mayne Pharma Group Ltd (MYX) has an Asset Resilience Ratio of 4.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Mayne Pharma Group Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$40.56 Million
≈ $28.70 Million USD Cash + Short-term Investments

Total Assets

AU$1.01 Billion
≈ $717.90 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Mayne Pharma Group Ltd's Asset Resilience Ratio has changed over time. See Mayne Pharma Group Ltd (MYX) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Mayne Pharma Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mayne Pharma Group Ltd stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$40.56 Million 4.0%
Total Liquid Assets AU$40.56 Million 4.00%

Asset Resilience Insights

  • Limited Liquidity: Mayne Pharma Group Ltd maintains only 4.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Mayne Pharma Group Ltd Industry Peers by Asset Resilience Ratio

Compare Mayne Pharma Group Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sigma Healthcare Ltd
AU:SIG
Medical Distribution 0.03%
Cyclopharm Ltd
AU:CYC
Medical Distribution 1.98%
Ebos Group Ltd
AU:EBO
Medical Distribution 0.00%
Paragon Care Ltd
AU:PGC
Medical Distribution 0.00%
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
Medical Distribution 4.48%
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
Medical Distribution 4.44%
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332
Medical Distribution 5.56%
Jointown Pharmaceutical Group Co Ltd
SHG:600998
Medical Distribution 0.08%

Annual Asset Resilience Ratio for Mayne Pharma Group Ltd (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Mayne Pharma Group Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 4.00% AU$40.56 Million
≈ $28.70 Million
AU$1.01 Billion
≈ $717.90 Million
+0.57pp
2024-06-30 3.43% AU$39.21 Million
≈ $27.74 Million
AU$1.14 Billion
≈ $808.87 Million
-6.79pp
2023-06-30 10.22% AU$127.53 Million
≈ $90.23 Million
AU$1.25 Billion
≈ $882.58 Million
+0.32pp
2022-06-30 9.90% AU$127.53 Million
≈ $90.23 Million
AU$1.29 Billion
≈ $911.29 Million
+9.87pp
2019-06-30 0.03% AU$563.00K
≈ $398.36K
AU$1.64 Billion
≈ $1.16 Billion
-0.33pp
2018-06-30 0.37% AU$6.75 Million
≈ $4.77 Million
AU$1.83 Billion
≈ $1.30 Billion
+0.04pp
2017-06-30 0.32% AU$6.21 Million
≈ $4.39 Million
AU$1.91 Billion
≈ $1.35 Billion
+0.10pp
2016-06-30 0.22% AU$3.46 Million
≈ $2.45 Million
AU$1.56 Billion
≈ $1.10 Billion
-0.20pp
2015-06-30 0.42% AU$2.23 Million
≈ $1.58 Million
AU$528.95 Million
≈ $374.26 Million
-0.02pp
2014-06-30 0.44% AU$1.17 Million
≈ $829.26K
AU$265.82 Million
≈ $188.08 Million
-0.34pp
2013-06-30 0.78% AU$1.82 Million
≈ $1.29 Million
AU$233.39 Million
≈ $165.14 Million
--
pp = percentage points

About Mayne Pharma Group Ltd

AU:MYX Australia Medical Distribution
Market Cap
$159.81 Million
AU$225.86 Million AUD
Market Cap Rank
#17374 Global
#518 in Australia
Share Price
AU$2.78
Change (1 day)
-2.11%
52-Week Range
AU$2.13 - AU$7.12
All Time High
AU$41.75
About

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more